CBO Doubts Aside, Wellness And Prevention Look Strong In Health Reform
This article was originally published in The Pink Sheet Daily
Under CBO's budget scorekeeping rules, prevention and wellness activities do not produce sufficiently demonstrable and quantifiable savings in the near term to qualify as offsets to appropriations, but a general cost-benefit analysis more accurately reflects the costs and benefits of interventions, experts say.
You may also be interested in...
If AstraZeneca gets JUPITER results on label, it could improve reimbursement for the indication in patients with healthy cholesterol levels but biomarker for inflammation and at least one CVD risk factor.
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.